Oxapenems are a class of molecules with a fivewith a double bond between C-2 and C-3. Early compounds were either of low4) or moderate5) chemical stability.
However, PFAENDLER et al.6) achieved enhanced stability by the introduction of a bulky tertiary-alkyl group at C-2. The lead compound from this series, AM-113 (1a), possessed antimicrobial activity particularly against staphylococci.7)
Further studies showed that AM-113 and other analogues activity, including potent activity against Class C enzymes. As an example of the preparation of the compounds in Table 1 , the synthesis of AM-114 (1x) is shown in Scheme 1. The commercially available azetidinone (5) was converted to the methylthio analogue (6) by treatment with sodium methylmercaptide. This was alkylated by deprotonation with n-butyl lithium and reaction with p-nitrobenzyl iodoacetate to give the ester (7), which was in turn acylated by treatment with lithium ketoester (8). The next stage was to invert the configuration of the hydroxyethyl group. This was achieved by way of a Mitsunobu reaction in which the alcohol (9) was converted to the formate ester (10), which was then selectively hydrolysed with hydrochloric acid in methanol and water to
give the alcohol of the opposite stereochemistry (11). After protection of the alcohol as the p-nitrobenzyl carbonate (12) the azetidinone was activated for ring closure as the chloro analogue (13). When this compound was treated For compounds 2(a-d), 3(a and b) and 4(a-c) the absolute stereochemistry is the opposite of that shown in Table 1 . However, for consistency within Table 1 , that shown assumes that R1 has lowest priority and is hence comparable to all other compounds in the Table. The compounds of Table 1 are either single enantiomers (Errant.) or a racemic mixture (Rac.).
aZone diameter determined using disc diffusion (IsoSensitest agar swabbed with a culture of each bacterial strain adjusted to an inoculum density corresponding to a 0.5
McFarland standard). with a base ring-closure occurred to give the oxapenem (14) in which the trans isomer shown was the major product (typically traps:cis was 2:1). Finally, hydrogenolysis led to a double deprotection of the alcohol and acid to give AM-114 (1x). Other compounds shown in Table 1 were made by similar methods.6,7,13-17) Results and Discussion A total of 35 oxapenems were synthesised and screened for synergy with ceftazidime (CAZ), using disc diffusion, against six strains representing a range of bacterial species (Table 1) . These data allowed the following general structure activity relationships to be made. Within series 1 (R1=Me, 1a-z) when the (R) stereochemistry is present, all substitutions at R2 enhanced the activity of ceftazidime to a similar extent against Escherichia coli and Enterobacter cloacae strains producing Class A and Class isolate.
None of the analogues enhanced ceftazidime activity against Pseudomonas aeruginosa ATCC 27853.
The synergistic activity against E. faecalis HRP-1 was lost in series 1 when the (S) stereochemistry was present (1x-z). Introduction of cyclic groups at R1 (series 2, 3 and 4) generated analogues which markedly enhanced ceftazidime zone diameter against S. aureus 25768, but had no beneficial effect against the Gram-negative strains. The requirement for (R) stereochemistry when R1=Me (series 1) to achieve activity was not apparent in these series. When R1 was a cyclic group, both (R) and (S)
configurations exhibited synergistic interactions with ceftazidime against E. faecalis. Eleven analogues from series 1, representing both salts and zwitterionic compounds, were selected for further against other bacterial species (Table 2) . The potential of the selected analogues to enhance ceftazidime activity was confirmed in MIC tests against The unexpected but C-1' stereospecific synergy against E. faecalis was also confirmed in MIC tests (Table 4) . Further tests (not shown) showed that this synergy extended to Enterococcus casseflavus and Enterococcus gallinarum but was less evident against Enterococcus faecium.
AM-112, AM-113, AM-114 and AM-115 exhibited potent broad spectrum inhibition of isolated Class A, C and tests, the (S) stereoisomers AM-114 and AM-115 were the most potent analogues, suggesting that other factors such as lactamase inhibitory activity of the zwitterionic compounds AM-112 and AM-115 against cellular enclosed enzymes. Following subcutaneous dosing at 50mg/kg in mice, detectable serum levels of the zwitterions AM-112 and AM-115 were achieved for 30 minutes (Figure 1 ). Lower levels were observed for the non zwitterionic analogue of AM-115 (i.e. AM-114), but the corresponding analogue of AM-112 (i. e. AM-113) was not detectable. In contrast, following oral dosing, only AM-114 gave detectable serum levels, indicating approximately 30% bioavailability ( Figure   2 ). In serum stability studies, HPLC analysis showed no loss of AM-112, AM-114 or AM-115 following incubation for 60 minutes in human and marmoset sera and only ca. 20% in mouse sera. In contrast, AM-113 exhibited marked losses in all sera types. The pH stability of AM-112 ranged from 0% loss at pH 6.5 to 28.4% loss at pH 8.5, over 6 hours.
The results of subsequent murine infection models confirmed the ability of AM-112 to enhance the activity of ceftazidime against infections caused by S. aureus or can be overcome by the introduction of a bulky tertiaryalkyl group at C-2.6) The lead compound AM-113 from these studies not only exhibited antibacterial activity against S. aureus but also potent inhibitory activity against and antibacterial activity of (1'R, 5R, 6R)-2-tert-butyl-6-(1'-hydroxyethyl)oxapenem-3-carboxylic acid. Bioorg. Med. Chem. Lett. 3: 2211 Lett. 3: -2218 Lett. 3: , 1993 Intersci.
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